Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
ANBL1531: A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Grant
Overview
Affiliation
Overview
Awarded By
CHILDREN'S HOSPITAL (PHILADELPHIA)
Total Award Amount
22000.00
Direct Costs
18333.00
Sponsor Award Id
Affiliation
Contributor
Matthew Kutny M.D.
Principal Investigator